Patents by Inventor Babak BAYAT

Babak BAYAT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HPV VACCINE MANUFACTURE
    Publication number: 20240131140
    Abstract: Described are methods for the preparation of a HPV vaccine composition by, for example (i) adsorbing one or more HPV antigen(s) on a metallic salt and, then (ii) adding a non adsorbed glycolipid based TLR4 ligand to the mixture obtained in (i). Resulting HPV vaccine compositions and uses thereof are also described.
    Type: Application
    Filed: February 9, 2022
    Publication date: April 25, 2024
    Applicants: GLAXOSMITHKLINE BIOLOGICALS SA, XIAMEN INNOVAX BIOTECH CO., LTD.
    Inventors: Babak BAYAT, Véronique HENDERICKX, Bram VUYLSTEKE
  • Hepatitis B immunization regimen and compositions
    Patent number: 11957749
    Abstract: The present invention relates to immunogenic compositions and combinations thereof which may find use in immunisation regimens for the treatment of chronic hepatitis B. An immunogenic composition comprises a replication-defective chimpanzee adenoviral (ChAd) vector comprising polynucleotides encoding HBs, HBc human invariant chain (hIi) fused to the HBc. Another immunogenic composition comprises a Modified Vaccinia Virus Ankara (MVA) vector comprising polynucleotides encoding HBs and HBc. Another immunogenic composition comprises recombinant HBs, C-terminal truncated recombinant HBc and an adjuvant containing MPL and QS-21.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: April 16, 2024
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Virginia Ammendola, Babak Bayat, Clarisse Lorin, Ventzislav Bojidarov Vassilev, Alessandra Vitelli
  • HEPATITIS B IMMUNISATION REGIMEN AND COMPOSITIONS
    Publication number: 20220339281
    Abstract: There is provided a method of treating chronic hepatitis B infection (CHB) and/or chronic hepatitis D infection (CHD) in a human, comprising the steps of: a) administering to the human a composition comprising an antisense oligonucleotide (ASO) 10 to 30 nucleosides in length, targeted to a HBV nucleic acid (an HBV ASO); b) administering to the human a composition comprising a replication-defective chimpanzee adenoviral (ChAd) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc); c) administering to the human a composition comprising a Modified Vaccinia Virus Ankara (MVA) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc); and d) administering to the human a composition comprising a recombinant hepatitis B surface antigen (HBs), recombinant hepatitis B virus core antigen (HBc) and an adjuvant.
    Type: Application
    Filed: March 4, 2020
    Publication date: October 27, 2022
    Inventors: Babak BAYAT, Robert Kiyoshi HAMATAKE, Clarisse Marie Madeleine LORIN, Ventzislav Bojidarov VASSILEV, Lucile Eve-Renee WARTER, Shihy Kieffer YOU
  • HEPATITIS B IMMUNISATION REGIMEN AND COMPOSITIONS
    Publication number: 20210154290
    Abstract: The present invention relates to immunogenic compositions and combinations thereof which may find use in immunisation regimens for the treatment of chronic hepatitis B. An immunogenic composition comprises a replication-defective chimpanzee adenoviral (ChAd) vector comprising polynucleotides encoding HBs, HBc human invariant chain (hIi) fused to the HBc. Another immunogenic composition comprises a Modified Vaccinia Virus Ankara (MVA) vector comprising polynucleotides encoding HBs and HBc. Another immunogenic composition comprises recombinant HBs, C-terminal truncated recombinant HBc and an adjuvant containing MPL and QS-21.
    Type: Application
    Filed: December 14, 2018
    Publication date: May 27, 2021
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Virginia AMMENDOLA, Babak BAYAT, Clarisse LORIN, Ventzislav Bojidarov VASSILEV, Alessandra VITELLI
  • HEPATITIS B IMMUNISATION REGIMEN AND COMPOSITIONS
    Publication number: 20210069322
    Abstract: There is provided a method of treating chronic hepatitis B infection (CHB) in a human, comprising the steps of: a) administering to the human a composition comprising a replication-defective chimpanzee adenoviral (ChAd) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc); b) administering to the human a composition comprising a Modified Vaccinia Virus Ankara (MVA) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc); and c) administering to the human a composition comprising a recombinant hepatitis B surface antigen (HBs), recombinant hepatitis B virus core antigen (HBc) and an adjuvant.
    Type: Application
    Filed: December 14, 2018
    Publication date: March 11, 2021
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Virginia AMMENDOLA, Babak BAYAT, Clarisse LORIN, Ventzislav Bojidarov VASSILEV, Alessandra VITELLI